SG11201808909WA - Ex vivo bite-activated t cells - Google Patents

Ex vivo bite-activated t cells

Info

Publication number
SG11201808909WA
SG11201808909WA SG11201808909WA SG11201808909WA SG11201808909WA SG 11201808909W A SG11201808909W A SG 11201808909WA SG 11201808909W A SG11201808909W A SG 11201808909WA SG 11201808909W A SG11201808909W A SG 11201808909WA SG 11201808909W A SG11201808909W A SG 11201808909WA
Authority
SG
Singapore
Prior art keywords
madrid
calle
parque
santiago
pcm
Prior art date
Application number
SG11201808909WA
Inventor
Nobell Juan Antonio Ballesteros
Teresa Ann Bennet
Campo Pilar Hernández
González Cristina Gómez
Guillén Julián Gorrochategui
López Joaquín Martínez
Mateos Alicia Robles
Ramos Daniel Primo
Original Assignee
Vivia Biotech Sl
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Vivia Biotech Sl filed Critical Vivia Biotech Sl
Publication of SG11201808909WA publication Critical patent/SG11201808909WA/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001102—Receptors, cell surface antigens or cell surface determinants
    • A61K39/001103—Receptors for growth factors
    • A61K39/001106—Her-2/neu/ErbB2, Her-3/ErbB3 or Her 4/ErbB4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001102—Receptors, cell surface antigens or cell surface determinants
    • A61K39/001103—Receptors for growth factors
    • A61K39/001109—Vascular endothelial growth factor receptors [VEGFR]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001102—Receptors, cell surface antigens or cell surface determinants
    • A61K39/001103—Receptors for growth factors
    • A61K39/00111—Hepatocyte growth factor receptor [HGFR or c-met]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001102—Receptors, cell surface antigens or cell surface determinants
    • A61K39/001111—Immunoglobulin superfamily
    • A61K39/001112—CD19 or B4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001102—Receptors, cell surface antigens or cell surface determinants
    • A61K39/001122—Ephrin Receptors [Eph]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001102—Receptors, cell surface antigens or cell surface determinants
    • A61K39/001124—CD20
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001102—Receptors, cell surface antigens or cell surface determinants
    • A61K39/001129—Molecules with a "CD" designation not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/00113—Growth factors
    • A61K39/001135—Vascular endothelial growth factor [VEGF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001166—Adhesion molecules, e.g. NRCAM, EpCAM or cadherins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001169—Tumor associated carbohydrates
    • A61K39/00117—Mucins, e.g. MUC-1
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001169—Tumor associated carbohydrates
    • A61K39/001171—Gangliosides, e.g. GM2, GD2 or GD3
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/00118—Cancer antigens from embryonic or fetal origin
    • A61K39/001182—Carcinoembryonic antigen [CEA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001193—Prostate associated antigens e.g. Prostate stem cell antigen [PSCA]; Prostate carcinoma tumor antigen [PCTA]; PAP or PSGR
    • A61K39/001195—Prostate specific membrane antigen [PSMA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/461—Cellular immunotherapy characterised by the cell type used
    • A61K39/4611—T-cells, e.g. tumor infiltrating lymphocytes [TIL], lymphokine-activated killer cells [LAK] or regulatory T cells [Treg]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
    • A61K39/4643—Vertebrate antigens
    • A61K39/4644—Cancer antigens
    • A61K39/464402—Receptors, cell surface antigens or cell surface determinants
    • A61K39/464411—Immunoglobulin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
    • A61K39/4643—Vertebrate antigens
    • A61K39/4644—Cancer antigens
    • A61K39/464402—Receptors, cell surface antigens or cell surface determinants
    • A61K39/464411—Immunoglobulin superfamily
    • A61K39/464412—CD19 or B4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
    • A61K39/4643—Vertebrate antigens
    • A61K39/4644—Cancer antigens
    • A61K39/464402—Receptors, cell surface antigens or cell surface determinants
    • A61K39/464416—Receptors for cytokines
    • A61K39/464419—Receptors for interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/05—Immunological preparations stimulating the reticulo-endothelial system, e.g. against cancer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • C12N5/0637—Immunosuppressive T lymphocytes, e.g. regulatory T cells or Treg
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • C12N5/0638—Cytotoxic T lymphocytes [CTL] or lymphokine activated killer cells [LAK]
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5011—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing antineoplastic activity
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells
    • A61K2039/5158—Antigen-pulsed cells, e.g. T-cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A61K2039/572—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 cytotoxic response
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
    • A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterised by the cancer treated
    • A61K2239/48—Blood cells, e.g. leukemia or lymphoma
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/50—Cell markers; Cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/50—Cell markers; Cell surface determinants
    • C12N2501/505—CD4; CD8
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/50—Cell markers; Cell surface determinants
    • C12N2501/515—CD3, T-cell receptor complex
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/50—Cell markers; Cell surface determinants
    • C12N2501/599—Cell markers; Cell surface determinants with CD designations not provided for elsewhere

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Microbiology (AREA)
  • Medicinal Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Oncology (AREA)
  • Cell Biology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Organic Chemistry (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Hematology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Developmental Biology & Embryology (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Toxicology (AREA)

Abstract

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property -, Organization 111111110111101110101011111 010111110111010111 ME1001111101111111011110111111 International Bureau ... ..... ..Yi j (10) International Publication Number ..... .....!;,,, (43) International Publication Date WO 2017/178572 Al 19 October 2017(19.10.2017) WIPO I PCT (51) International Patent Classification: BIOTECH, S.L, Parque Cientifico Madrid (PCM), 1, Calle A61K 39/00 (2006.01) Santiago Grisolia, Suite 205, 28760 Madrid (ES). (21) International Application Number: (74) Agent: ILLESCAS TABOADA, Manuel; C/ Principe de PCT/EP2017/058891 Vergara, 197, Oficina 1° A, 28002 Madrid (ES). (22) International Filing Date: (81) Designated States (unless otherwise indicated, for every 12 April 2017 (12.04.2017) kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, (25) Filing Language: English BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, (26) Publication Language: English DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KH, KN, (30) Priority Data: 62/321,964 13 April 2016 (13.04.2016) US KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, (71) Applicant: V1VIA BIOTECH, S.L [ES/ES]; Parque Cien- tifico Madrid (PCM), 1, Calle Santiago Grisolia, Suite 205, 28760 Madrid (ES). NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. (72) Inventors: BALLESTEROS NOBELL, Juan Antonio; VWIA BIOTECH, S.L, Parque Cientifico Madrid (PCM), 1, Calle Santiago Grisolia, Suite 205, 28760 Madrid (ES). BENNET, Teresa Ann; VWIA BIOTECH, S.L, Parque Cientifico Madrid (PCM), 1, Calle Santiago Grisolia, Suite 205, 28760 Madrid (ES). HERNANDEZ CAMPO, Pilar; VWIA BIOTECH, S.L, Parque Cientifico Madrid (PCM), 1, Calle Santiago Grisolia, Suite 205, 28760 Madrid (ES). GOMEZ GONZALEZ, Cristina; VWIA BIOTECH, S.L, Parque Cientifico Madrid (PCM), 1, Calle Santiago Griso- (84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG). — _ = = lia, Suite 205, 28760 Madrid (ES). GORROCHATEGUI Published: GUILLEN, Julian; VWIA BIOTECH, S.L, Parque Cien- — tifico Madrid (PCM), 1, Calle Santiago Grisolia, Suite 205, — with international search report (Art. 21(3)) = = 28760 Madrid (ES). MARTINEZ LOPEZ, Joaquin; — before the expiration of the time limit for amending the Calle Melilla num. 6 6°B, 28005 Madrid (ES). ROBLES claims and to be republished in the event of receipt of — MATEOS, Alicia; VWIA BIOTECH, S.L, Parque Cienti- fico Madrid (PCM), 1, Calle Santiago Grisolia, Suite 205, 28760 Madrid (ES). PRIMO RAMOS, Daniel; VWIA amendments (Rule 48.2(h)) = = = = = = = = 1-1 ei IN kin cc IN 1-1 (54) Title: EX VIVO BITE-ACTIVATED T CELLS I r ----- (57) : Generation and identification of highly effective immune effector cell in terms of target cell-killing activity can be en- 1-1 hanced by optimizing the proximity between a target cell and the immune effector cell. The cancer-killing T cells described herein ei can provide highly effective therapies for diverse cancer types, e.g., solid cancers, hematological cancers, and metastatic forms there - tom.) of. Provided herein are ex-vivo methods of generating cancer-killing T cells, compositions comprising such immune cells; methods ,7 1 1 . 9 of using the cells, methods of selecting optimal agents for enhancing the target cell killing activity, methods of selecting an optim- ized immune cell and methods of using this approach to evaluate patient responsiveness to other cancer therapies.
SG11201808909WA 2016-04-13 2017-04-12 Ex vivo bite-activated t cells SG11201808909WA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201662321964P 2016-04-13 2016-04-13
PCT/EP2017/058891 WO2017178572A1 (en) 2016-04-13 2017-04-12 Ex vivo bite-activated t cells

Publications (1)

Publication Number Publication Date
SG11201808909WA true SG11201808909WA (en) 2018-11-29

Family

ID=58669776

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11201808909WA SG11201808909WA (en) 2016-04-13 2017-04-12 Ex vivo bite-activated t cells

Country Status (11)

Country Link
US (1) US20190218515A1 (en)
EP (1) EP3445391A1 (en)
JP (2) JP7038353B2 (en)
KR (1) KR20180133442A (en)
CN (2) CN117327650A (en)
AU (2) AU2017249698B2 (en)
CA (1) CA3020830A1 (en)
IL (2) IL295538B2 (en)
MX (2) MX2018012488A (en)
SG (1) SG11201808909WA (en)
WO (1) WO2017178572A1 (en)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG11201708680PA (en) * 2016-03-31 2017-11-29 Lion Tcr Pte Ltd Non-activated t cells expressing exogenous virus-specific t cell receptor (tcr)
TW201843177A (en) * 2017-04-11 2018-12-16 美商英伊布里克斯公司 Multispecific polypeptide constructs having constrained cd3 binding and methods of using the same
CA3079310A1 (en) * 2017-10-18 2019-04-25 Vivia Biotech, S.L. Bite-activated car-t cells
CA3083950A1 (en) * 2017-12-01 2019-06-06 Soricimed Biopharma Inc. Trpv6 inhibitors and combination therapies for treating cancers
AU2019215096A1 (en) * 2018-02-02 2020-08-06 Wake Forest University Health Sciences Organoids related to immunotherapy and methods of preparing and using the same
BR112020018658A2 (en) 2018-03-15 2020-12-29 KSQ Therapeutics, Inc. GENE REGULATION COMPOSITIONS AND METHODS FOR IMPROVED IMU-NOTERAPY
IL271325B1 (en) * 2018-03-27 2024-05-01 Systimmune Inc Guidance and navigation control proteins and method of making and using thereof
WO2020043903A1 (en) * 2018-08-31 2020-03-05 Invectys Method to assess car functionality
AU2020403153A1 (en) * 2019-12-11 2022-06-30 Cullinan Oncology, Inc. Anti-serum albumin antibodies
CA3161283A1 (en) * 2019-12-11 2021-06-17 Cullinan Oncology, Inc. Anti-cd19 antibodies and multi-specific binding proteins
JP2023550148A (en) 2020-11-20 2023-11-30 シンシア・イノベーション・インコーポレイテッド Armed dual CAR-T compositions and methods used in cancer immunotherapy
CA3216524A1 (en) 2021-04-12 2022-10-20 Medgene Therapeutics, Inc. A method of activating and proliferating exhausted cd8 t cells, cd8 t cells with enhanced activity prepared by the same, and use thereof
US20230313140A1 (en) * 2022-04-04 2023-10-05 St. Jude Children's Research Hospital, Inc. Method for preparing t cells for adoptive t cell therapy

Family Cites Families (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5811097A (en) 1995-07-25 1998-09-22 The Regents Of The University Of California Blockade of T lymphocyte down-regulation associated with CTLA-4 signaling
DE69839147T2 (en) 1997-06-12 2009-02-19 Novartis International Pharmaceutical Ltd. ARTIFICIAL ANTIBODY POLYPEPTIDE
AUPP221098A0 (en) 1998-03-06 1998-04-02 Diatech Pty Ltd V-like domain binding molecules
PT1071752E (en) * 1998-04-21 2003-11-28 Micromet Ag SPECIFIC POLYMPEPTIDES FOR CD19XCD3 AND ITS USES
US6818418B1 (en) 1998-12-10 2004-11-16 Compound Therapeutics, Inc. Protein scaffolds for antibody mimics and other binding proteins
ES2329959T5 (en) 1998-12-10 2013-12-18 Bristol-Myers Squibb Company Protein frameworks for antibody mimetics and other binding proteins
AU4499499A (en) 1999-04-01 2000-10-23 Innogenetics N.V. A polypeptide structure for use as a scaffold
JP2004538331A (en) * 2001-08-17 2004-12-24 ロジャー ウィリアムス ホスピタル In situ immunization
AU2003209272A1 (en) 2002-01-16 2003-09-02 Zyomyx, Inc. Engineered binding proteins
AU2003265948B8 (en) 2002-09-06 2009-09-03 The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Immunotherapy with in vitro-selected antigen-specific lymphocytes after nonmyeloablative lymphodepleting chemotherapy
ES2367430T3 (en) 2002-12-23 2011-11-03 Wyeth Llc ANTIBODIES AGAINST PD-1 AND ITS USES.
US7501121B2 (en) 2004-06-17 2009-03-10 Wyeth IL-13 binding agents
RU2406760C3 (en) 2005-05-09 2017-11-28 Оно Фармасьютикал Ко., Лтд. HUMAN MONOCLONAL ANTIBODIES TO PROGRAMMABLE DEATH 1 PROTECTION (PD-1) AND METHODS OF CANCER TREATMENT USING ANTI-PD-1-ANTI-BODY, INDEPENDENTLY OR IN COMBINATION WITH OTHER IMMUNETURAH AND I And I And I And I, In The Combine, I And I Do Not Allocate To Them, Combined With Other Overarching
CN101248089A (en) 2005-07-01 2008-08-20 米德列斯公司 Human monoclonal antibodies to programmed death ligand 1(PD-L1)
AU2007225300B2 (en) 2006-03-10 2012-11-15 Vivia Biotech S.L. High speed sample supply device
SI2170959T1 (en) 2007-06-18 2014-04-30 Merck Sharp & Dohme B.V. Antibodies to human programmed death receptor pd-1
BRPI0907718A2 (en) 2008-02-11 2017-06-13 Curetech Ltd method for treating a tumor, method for improving tolerability to at least one chemotherapeutic agent, method for increasing survival of an individual having a tumor, method for reducing or preventing tumor recurrence, use of a humanized monoclonal antibody or fragment and antibody thereof humanized monoclonal or fragment thereof
EP2262837A4 (en) 2008-03-12 2011-04-06 Merck Sharp & Dohme Pd-1 binding proteins
US20100260668A1 (en) * 2008-04-29 2010-10-14 Abbott Laboratories Dual Variable Domain Immunoglobulins and Uses Thereof
AR072999A1 (en) 2008-08-11 2010-10-06 Medarex Inc HUMAN ANTIBODIES THAT JOIN GEN 3 OF LYMPHOCYTARY ACTIVATION (LAG-3) AND THE USES OF THESE
SI2350129T1 (en) 2008-08-25 2015-11-30 Amplimmune, Inc. Compositions of pd-1 antagonists and methods of use
BRPI0917891A2 (en) 2008-08-25 2015-11-24 Amplimmune Inc pd-1 antagonists and methods of using them
CN104479018B (en) 2008-12-09 2018-09-21 霍夫曼-拉罗奇有限公司 Anti- PD-L1 antibody and they be used to enhance the purposes of T cell function
JP5844159B2 (en) 2009-02-09 2016-01-13 ユニヴェルシテ デクス−マルセイユＵｎｉｖｅｒｓｉｔｅ Ｄ’Ａｉｘ−Ｍａｒｓｅｉｌｌｅ PD-1 antibody and PD-L1 antibody and use thereof
TWI546537B (en) 2009-05-19 2016-08-21 維維亞生技公司 Methods for providing personalized medicine tests ex vivo for hematological neoplasms
JP2013512251A (en) 2009-11-24 2013-04-11 アンプリミューン、インコーポレーテッド Simultaneous inhibition of PD-L1 / PD-L2
HUE040213T2 (en) 2010-06-11 2019-02-28 Kyowa Hakko Kirin Co Ltd Anti-tim-3 antibody
US20120244133A1 (en) 2011-03-22 2012-09-27 The United States of America, as represented by the Secretary, Department of Health and Methods of growing tumor infiltrating lymphocytes in gas-permeable containers
EA036814B9 (en) 2011-11-28 2021-12-27 Мерк Патент Гмбх Anti-pd-l1 antibody (embodiments), composition comprising this antibody and use thereof
AR091649A1 (en) 2012-07-02 2015-02-18 Bristol Myers Squibb Co OPTIMIZATION OF ANTIBODIES THAT FIX THE LYMPHOCYTE ACTIVATION GEN 3 (LAG-3) AND ITS USES
CN109513003A (en) * 2012-08-14 2019-03-26 Ibc药品公司 T- cell for treating disease redirects bispecific antibody
CA2899577C (en) * 2013-04-03 2023-10-17 Ibc Pharmaceuticals, Inc. Combination therapy for inducing immune response to disease
CA2937236C (en) * 2014-02-21 2023-03-07 Ibc Pharmaceuticals, Inc. Disease therapy by inducing immune response to trop-2 expressing cells

Also Published As

Publication number Publication date
MX2022006444A (en) 2022-06-22
EP3445391A1 (en) 2019-02-27
JP2022081509A (en) 2022-05-31
IL262359B (en) 2022-09-01
IL262359A (en) 2018-11-29
IL295538B2 (en) 2024-02-01
JP2019513400A (en) 2019-05-30
CN117327650A (en) 2024-01-02
MX2018012488A (en) 2019-06-06
AU2017249698A1 (en) 2018-11-08
CN109789195A (en) 2019-05-21
AU2023203601A1 (en) 2023-07-06
JP7038353B2 (en) 2022-03-18
IL295538B1 (en) 2023-10-01
AU2017249698B2 (en) 2023-03-09
IL295538A (en) 2022-10-01
KR20180133442A (en) 2018-12-14
CA3020830A1 (en) 2017-10-19
WO2017178572A1 (en) 2017-10-19
US20190218515A1 (en) 2019-07-18

Similar Documents

Publication Publication Date Title
SG11201808909WA (en) Ex vivo bite-activated t cells
SG11201811290VA (en) Compositions and methods for the depletion of cd117+cells
SG11201808920RA (en) Genome editing of human neural stem cells using nucleases
SG11201901531TA (en) Regulation of gene expression using engineered nucleases
SG11201810048VA (en) Tri-segmented pichinde viruses as vaccine vectors
SG11201809710RA (en) Genetically engineered cells and methods of making the same
SG11201811431VA (en) Multispecific antibodies against cd40 and cd137
SG11201804901WA (en) Compounds for the treatment of cancer and inflammatory disease
SG11201804814YA (en) Materials and methods for delivering nucleic acids to cochlear and vestibular cells
SG11201803851TA (en) Fuel components from hydroprocessed deasphalted oils
SG11201901841TA (en) Targeting ligands
SG11201805888SA (en) Cyclic dinucleotides for treating conditions associated with sting activity such as cancer
SG11202000145XA (en) Methods and systems for conditionally regulating gene expression
SG11201803593QA (en) Engineered nucleic-acid targeting nucleic acids
SG11201805052YA (en) Therapeutic methods using erythrocytes
SG11201804220SA (en) Activated stem cells and systemic treatment methods for infected wounds
SG11201903013SA (en) Targeted delivery of nicotinamide adenine dinucleotide salvage pathway inhibitors
SG11201810525XA (en) Anti-gitr antibodies and uses thereof
SG11201807827VA (en) Process for the preparation of pegylated drug-linkers and intermediates thereof
SG11201808762XA (en) Diagnostic methods for patient specific therapeutic decision making in cancer care
SG11201804888WA (en) Velocity model update with an inversion gradient
SG11201805001UA (en) Method of treating influenza a
SG11201806480UA (en) Derivatives of pyrroloimidazole or analogues thereof which are useful for the treatment of inter alia cancer
SG11201808964PA (en) Antisense oligomers and methods of using the same for treating diseases associated with the acid alpha-glucosidase gene
SG11201806211VA (en) Small crystal, high surface area emm-30 zeolites, their synthesis and use